<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tenax Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/tenax-therapeutics-inc</link>
<description>Latest news and press releases for Tenax Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tenax-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c8b178dffbe2df11bfa3.webp</url>
<title>Tenax Therapeutics Inc</title>
<link>https://6ix.com/company/tenax-therapeutics-inc</link>
</image>
<item>
<title>Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-appoints-thomas-r-staab-ii-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-appoints-thomas-r-staab-ii-as-chief-financial-officer</guid>
<pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
<description>Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Thomas R. Staab, II as Chief Financial Officer (CFO), effective May 11, 2026. Mr. Staab brings over 25</description>
</item>
<item>
<title>Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial</description>
</item>
<item>
<title>Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-to-participate-in-the-2026-leerink-partners-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-to-participate-in-the-2026-leerink-partners-global-healthcare-conference</guid>
<pubDate>Tue, 03 Mar 2026 12:00:00 GMT</pubDate>
<description>CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference, which is taking place from March 8-11, 2026, in Miami, FL. Details of presentation:Format: Fireside chatPa</description>
</item>
<item>
<title>Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-participate-guggenheim-emerging-120000229</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-participate-guggenheim-emerging-120000229</guid>
<pubDate>Wed, 04 Feb 2026 12:00:00 GMT</pubDate>
<description>CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026, which is taking place from February 11-12, 2026, in New York, NY. Details of presentation:Format: Fireside ch</description>
</item>
<item>
<title>Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-announces-result-prespecifed-141600063</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-announces-result-prespecifed-141600063</guid>
<pubDate>Wed, 17 Dec 2025 14:16:00 GMT</pubDate>
<description>Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3 LEVEL-2 Study Initiated; Company Estimates Completion of Enrollment by End of 2027 CHAPEL HILL, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company u</description>
</item>
<item>
<title>Tenax Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-participate-upcoming-investor-120000848</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-participate-upcoming-investor-120000848</guid>
<pubDate>Tue, 25 Nov 2025 12:00:00 GMT</pubDate>
<description>CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the following investor conferences: 8th Annual Evercore Healthcare ConferenceFormat: Fireside chatParticipants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical</description>
</item>
<item>
<title>Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-reports-third-quarter-210500636</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-reports-third-quarter-210500636</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 Tenax to Host Virtual KOL Call Tomorrow, Thursday, November 13, 2025 at 4:30 p.m. ET CHAPEL HILL, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clin</description>
</item>
<item>
<title>Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-host-virtual-kol-120000134</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-host-virtual-kol-120000134</guid>
<pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
<description>CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will host a conference call and webcast on Thursday, November 13, 2025, at 4:30 p.m. ET. Members of the management team will be joined by the below recognized key opinion leaders in cardiovascular medicine to disc</description>
</item>
<item>
<title>Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-participate-guggenheim-2nd-120000704</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-participate-guggenheim-2nd-120000704</guid>
<pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
<description>CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is taking place from November 10-12, 2025, in Boston, MA. Details of presentation: Format: Fireside chat Participants: Chris Giorda</description>
</item>
<item>
<title>Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-announces-european-patent-110000282</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-announces-european-patent-110000282</guid>
<pubDate>Tue, 16 Sep 2025 11:00:00 GMT</pubDate>
<description>Provides Patent Protection in Europe Through at Least December 2040 Further IP Protection for TNX-103 (Oral Levosimendan) and Other Drug Formulations, and its Active Metabolites, in PH-HFpEF Also Provides Patent Protection for Wide Range of Levosimendan Doses, and its Use in Combination with Various Cardiovascular Drugs in PH-HFpEF CHAPEL HILL, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, developme</description>
</item>
<item>
<title>Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-participate-cantor-global-110000362</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-participate-cantor-global-110000362</guid>
<pubDate>Thu, 28 Aug 2025 11:00:00 GMT</pubDate>
<description>CHAPEL HILL, N.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will participate in a fireside chat at the Cantor Global Healthcare Conference 2025, which is taking place from September 3-5, 2025, in New York, NY. Details of presentation: Format: Fireside chat Participants: Ch</description>
</item>
<item>
<title>Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-reports-second-quarter-200500735</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-reports-second-quarter-200500735</guid>
<pubDate>Wed, 13 Aug 2025 20:05:00 GMT</pubDate>
<description>Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 CHAPEL HILL, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today reported financial re</description>
</item>
<item>
<title>Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-reports-first-quarter-200500879</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-reports-first-quarter-200500879</guid>
<pubDate>Wed, 14 May 2025 20:05:00 GMT</pubDate>
<description>Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today reported financial results for th</description>
</item>
<item>
<title>Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-participate-24th-annual-120000103</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-participate-24th-annual-120000103</guid>
<pubDate>Mon, 31 Mar 2025 12:00:00 GMT</pubDate>
<description>CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place virtually from April 7-10, 2025. Details of presentation: Format: Corporate Presentation Participants: Chris Giordano,</description>
</item>
<item>
<title>Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-reports-fourth-quarter-200500520</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-reports-fourth-quarter-200500520</guid>
<pubDate>Tue, 25 Mar 2025 20:05:00 GMT</pubDate>
<description>Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations through 2027 Phase 3 LEVEL Study Expansion Increases Statistical Power; Enrollment Completion Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeuti</description>
</item>
<item>
<title>Tenax Therapeutics Announces $25 Million Private Placement</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-announces-25-million-134700439</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-announces-25-million-134700439</guid>
<pubDate>Wed, 05 Mar 2025 13:47:00 GMT</pubDate>
<description>CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that it has entered into a securities purchase agreement for a private placement financing with RTW Investments, which is expected to result in total gross proceeds of approximately $25 million to the Company, before deducting pl</description>
</item>
<item>
<title>Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-expands-phase-3-134200908</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-expands-phase-3-134200908</guid>
<pubDate>Wed, 05 Mar 2025 13:42:00 GMT</pubDate>
<description>Amendment to Enlarge Phase 3 LEVEL Study, Increasing Statistical Powering, Accepted by FDA, Expected to be Fully Enrolled Around Year End 2025 Agreement by FDA to Initiate Second Global Phase 3 Study, LEVEL-2, with First Patient Expected to be Enrolled this Year CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopul</description>
</item>
<item>
<title>Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-participate-leerink-partners-130000915</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-participate-leerink-partners-130000915</guid>
<pubDate>Mon, 03 Mar 2025 13:00:00 GMT</pubDate>
<description>CHAPEL HILL, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company will participate in a fireside chat at the Leerink Partners 2025 Global Healthcare Conference, which is taking place from March 10-12,</description>
</item>
<item>
<title>Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-appoints-gillian-andor-vice-president-clinical-operations</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-appoints-gillian-andor-vice-president-clinical-operations</guid>
<pubDate>Wed, 22 Jan 2025 05:00:00 GMT</pubDate>
<description>CHAPEL HILL, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3,</description>
</item>
<item>
<title>Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-reports-third-quarter-2024-financial-results-and-provides-a-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/tenax-therapeutics-inc/news/tenax-therapeutics-reports-third-quarter-2024-financial-results-and-provides-a-corporate-update</guid>
<pubDate>Wed, 13 Nov 2024 05:00:00 GMT</pubDate>
<description>Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in</description>
</item>
</channel>
</rss>